Andrea Bonetto
Concepts (307)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Cachexia | 38 | 2026 | 75 | 13.110 |
Why?
| | Muscle, Skeletal | 35 | 2026 | 1796 | 3.900 |
Why?
| | Muscular Atrophy | 21 | 2026 | 89 | 3.830 |
Why?
| | Neoplasms | 15 | 2025 | 2884 | 2.070 |
Why?
| | Colorectal Neoplasms | 6 | 2022 | 848 | 1.830 |
Why?
| | Head and Neck Neoplasms | 6 | 2025 | 562 | 1.690 |
Why?
| | Ovarian Neoplasms | 6 | 2026 | 586 | 1.630 |
Why?
| | Camptothecin | 4 | 2024 | 140 | 1.500 |
Why?
| | Activin Receptors, Type II | 3 | 2021 | 12 | 1.330 |
Why?
| | STAT3 Transcription Factor | 5 | 2021 | 207 | 1.320 |
Why?
| | Liver Neoplasms | 5 | 2021 | 783 | 1.310 |
Why?
| | Myostatin | 6 | 2016 | 24 | 1.240 |
Why?
| | Mice | 35 | 2026 | 18365 | 1.120 |
Why?
| | Antineoplastic Combined Chemotherapy Protocols | 5 | 2024 | 1958 | 1.080 |
Why?
| | Disease Models, Animal | 16 | 2026 | 4569 | 1.040 |
Why?
| | Antineoplastic Agents | 6 | 2024 | 2197 | 1.020 |
Why?
| | Wasting Syndrome | 2 | 2020 | 12 | 1.000 |
Why?
| | Osteocytes | 4 | 2022 | 24 | 0.970 |
Why?
| | Bone and Bones | 5 | 2021 | 315 | 0.970 |
Why?
| | Animals | 44 | 2026 | 38109 | 0.940 |
Why?
| | Muscle Fibers, Skeletal | 6 | 2025 | 214 | 0.940 |
Why?
| | Musculoskeletal Development | 1 | 2025 | 6 | 0.940 |
Why?
| | Muscle Proteins | 7 | 2025 | 244 | 0.930 |
Why?
| | Vincristine | 1 | 2025 | 140 | 0.890 |
Why?
| | Antineoplastic Agents, Phytogenic | 1 | 2025 | 177 | 0.850 |
Why?
| | Masseter Muscle | 1 | 2024 | 3 | 0.850 |
Why?
| | Muscle Development | 1 | 2025 | 116 | 0.840 |
Why?
| | Interleukin-6 | 7 | 2026 | 780 | 0.820 |
Why?
| | Colonic Neoplasms | 4 | 2021 | 260 | 0.810 |
Why?
| | Bone Neoplasms | 2 | 2021 | 256 | 0.730 |
Why?
| | Cell Line, Tumor | 10 | 2025 | 3550 | 0.710 |
Why?
| | Glioblastoma | 1 | 2025 | 353 | 0.690 |
Why?
| | Bone Diseases, Metabolic | 1 | 2021 | 56 | 0.680 |
Why?
| | Weight Gain | 1 | 2025 | 559 | 0.670 |
Why?
| | Osteosarcoma | 1 | 2021 | 76 | 0.670 |
Why?
| | Neuropeptides | 1 | 2021 | 77 | 0.660 |
Why?
| | Muscles | 2 | 2013 | 333 | 0.640 |
Why?
| | Body Composition | 3 | 2018 | 706 | 0.620 |
Why?
| | Mice, Inbred C57BL | 11 | 2026 | 5997 | 0.610 |
Why?
| | X-Ray Microtomography | 4 | 2025 | 107 | 0.570 |
Why?
| | Muscular Dystrophies | 1 | 2017 | 30 | 0.530 |
Why?
| | Bone Density | 2 | 2018 | 482 | 0.510 |
Why?
| | Leucovorin | 4 | 2024 | 101 | 0.490 |
Why?
| | Male | 32 | 2026 | 72406 | 0.470 |
Why?
| | Fluorouracil | 4 | 2024 | 235 | 0.460 |
Why?
| | Brain Neoplasms | 1 | 2025 | 1322 | 0.460 |
Why?
| | Ubiquitin-Protein Ligases | 5 | 2025 | 193 | 0.450 |
Why?
| | Insulin-Like Growth Factor I | 3 | 2013 | 319 | 0.450 |
Why?
| | Stomach Neoplasms | 2 | 2013 | 128 | 0.420 |
Why?
| | Adenocarcinoma | 2 | 2021 | 931 | 0.420 |
Why?
| | MAP Kinase Signaling System | 1 | 2016 | 311 | 0.420 |
Why?
| | Tripartite Motif Proteins | 4 | 2025 | 40 | 0.360 |
Why?
| | Janus Kinases | 1 | 2012 | 20 | 0.360 |
Why?
| | Acute-Phase Reaction | 1 | 2011 | 37 | 0.350 |
Why?
| | SKP Cullin F-Box Protein Ligases | 3 | 2025 | 15 | 0.350 |
Why?
| | Humans | 35 | 2026 | 144957 | 0.340 |
Why?
| | Gene Expression Regulation, Neoplastic | 3 | 2021 | 1462 | 0.340 |
Why?
| | Sarcopenia | 2 | 2024 | 91 | 0.330 |
Why?
| | Female | 23 | 2026 | 78376 | 0.320 |
Why?
| | Down-Regulation | 4 | 2010 | 627 | 0.320 |
Why?
| | Glutamine | 1 | 2010 | 109 | 0.310 |
Why?
| | Follistatin | 1 | 2009 | 12 | 0.310 |
Why?
| | Muscular Disorders, Atrophic | 1 | 2009 | 2 | 0.300 |
Why?
| | Inflammation | 2 | 2023 | 2880 | 0.300 |
Why?
| | Valproic Acid | 1 | 2009 | 48 | 0.300 |
Why?
| | Musculoskeletal Diseases | 2 | 2022 | 90 | 0.300 |
Why?
| | Hydroxamic Acids | 1 | 2009 | 94 | 0.290 |
Why?
| | Energy Metabolism | 3 | 2020 | 936 | 0.290 |
Why?
| | Carcinoma, Lewis Lung | 2 | 2026 | 16 | 0.280 |
Why?
| | Cell Line | 5 | 2021 | 2882 | 0.270 |
Why?
| | Mitochondria, Muscle | 2 | 2020 | 121 | 0.270 |
Why?
| | Histone Deacetylase Inhibitors | 1 | 2009 | 220 | 0.260 |
Why?
| | Femur | 2 | 2021 | 250 | 0.260 |
Why?
| | Signal Transduction | 9 | 2021 | 5233 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 3 | 2010 | 1217 | 0.250 |
Why?
| | Glycogen Synthase Kinase 3 | 3 | 2013 | 81 | 0.250 |
Why?
| | Diet, High-Fat | 2 | 2026 | 261 | 0.250 |
Why?
| | Antioxidants | 1 | 2009 | 549 | 0.230 |
Why?
| | Cytoreduction Surgical Procedures | 1 | 2026 | 67 | 0.230 |
Why?
| | Free Tissue Flaps | 2 | 2024 | 45 | 0.220 |
Why?
| | DNA, Ribosomal | 2 | 2022 | 94 | 0.210 |
Why?
| | Osteoclasts | 2 | 2021 | 52 | 0.210 |
Why?
| | Bivalvia | 1 | 2023 | 7 | 0.200 |
Why?
| | Bile Acids and Salts | 1 | 2025 | 164 | 0.200 |
Why?
| | Mitochondria | 3 | 2022 | 984 | 0.190 |
Why?
| | Mice, Transgenic | 2 | 2022 | 2185 | 0.190 |
Why?
| | Cholesterol | 1 | 2025 | 408 | 0.190 |
Why?
| | Cytochromes | 1 | 2022 | 10 | 0.190 |
Why?
| | Peroxisome Proliferator-Activated Receptors | 1 | 2022 | 17 | 0.190 |
Why?
| | Cytokines | 4 | 2022 | 2065 | 0.190 |
Why?
| | Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha | 1 | 2022 | 40 | 0.190 |
Why?
| | Liver | 3 | 2025 | 1888 | 0.180 |
Why?
| | ROC Curve | 1 | 2024 | 615 | 0.180 |
Why?
| | Heterografts | 2 | 2022 | 144 | 0.180 |
Why?
| | Up-Regulation | 3 | 2016 | 852 | 0.180 |
Why?
| | Osteolysis | 1 | 2021 | 16 | 0.170 |
Why?
| | Sex Factors | 2 | 2024 | 2114 | 0.170 |
Why?
| | Subcutaneous Tissue | 1 | 2021 | 26 | 0.170 |
Why?
| | Receptors, Immunologic | 1 | 2022 | 206 | 0.170 |
Why?
| | Prognosis | 3 | 2024 | 4293 | 0.160 |
Why?
| | Cisplatin | 1 | 2022 | 334 | 0.160 |
Why?
| | Water Pollutants, Chemical | 1 | 2023 | 234 | 0.160 |
Why?
| | RNA, Ribosomal | 1 | 2021 | 168 | 0.160 |
Why?
| | Muscle Weakness | 1 | 2021 | 92 | 0.160 |
Why?
| | Mitochondrial Proteins | 1 | 2022 | 263 | 0.160 |
Why?
| | HCT116 Cells | 1 | 2020 | 78 | 0.150 |
Why?
| | Age Factors | 2 | 2024 | 3335 | 0.150 |
Why?
| | Ligands | 1 | 2021 | 674 | 0.150 |
Why?
| | Postoperative Complications | 3 | 2022 | 2920 | 0.150 |
Why?
| | Membrane Glycoproteins | 1 | 2022 | 496 | 0.150 |
Why?
| | Ribosomes | 1 | 2021 | 191 | 0.150 |
Why?
| | Epoprostenol | 1 | 2020 | 131 | 0.150 |
Why?
| | Receptor for Advanced Glycation End Products | 1 | 2019 | 31 | 0.150 |
Why?
| | Receptors, Ghrelin | 1 | 2018 | 7 | 0.150 |
Why?
| | Ghrelin | 1 | 2018 | 39 | 0.140 |
Why?
| | Muscle Strength | 2 | 2019 | 330 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2118 | 0.140 |
Why?
| | Nutrition Assessment | 1 | 2018 | 92 | 0.140 |
Why?
| | Cell Proliferation | 1 | 2026 | 2499 | 0.140 |
Why?
| | Protein Kinase Inhibitors | 2 | 2016 | 970 | 0.130 |
Why?
| | Muscle Contraction | 1 | 2021 | 429 | 0.130 |
Why?
| | Survival Analysis | 1 | 2021 | 1385 | 0.130 |
Why?
| | Induction Chemotherapy | 1 | 2017 | 87 | 0.130 |
Why?
| | Organ Size | 1 | 2018 | 463 | 0.130 |
Why?
| | Frailty | 1 | 2020 | 198 | 0.130 |
Why?
| | Drug Therapy | 1 | 2017 | 80 | 0.130 |
Why?
| | Aged | 7 | 2026 | 25947 | 0.130 |
Why?
| | Mice, Inbred Strains | 1 | 2017 | 397 | 0.130 |
Why?
| | Italy | 4 | 2023 | 114 | 0.130 |
Why?
| | Stroke Volume | 1 | 2020 | 651 | 0.120 |
Why?
| | Gastrointestinal Microbiome | 1 | 2025 | 771 | 0.120 |
Why?
| | Organoplatinum Compounds | 1 | 2016 | 66 | 0.120 |
Why?
| | Metformin | 1 | 2020 | 319 | 0.120 |
Why?
| | MAP Kinase Kinase 1 | 1 | 2016 | 71 | 0.120 |
Why?
| | Education, Medical | 1 | 1999 | 276 | 0.120 |
Why?
| | Hyperglycemia | 1 | 2020 | 375 | 0.120 |
Why?
| | Glycogen Synthase Kinase 3 beta | 3 | 2013 | 72 | 0.120 |
Why?
| | MicroRNAs | 1 | 2022 | 701 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 3 | 1 | 2016 | 138 | 0.120 |
Why?
| | Flavonoids | 1 | 2016 | 87 | 0.120 |
Why?
| | Myoblasts | 1 | 2016 | 84 | 0.120 |
Why?
| | Mitogen-Activated Protein Kinase 1 | 1 | 2016 | 175 | 0.110 |
Why?
| | Muscle Fatigue | 1 | 2016 | 97 | 0.110 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2016 | 266 | 0.110 |
Why?
| | Organ Specificity | 1 | 2016 | 313 | 0.110 |
Why?
| | Oxidation-Reduction | 1 | 2019 | 1087 | 0.110 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2017 | 257 | 0.110 |
Why?
| | Gene Expression | 1 | 2020 | 1490 | 0.110 |
Why?
| | Middle Aged | 7 | 2026 | 35928 | 0.110 |
Why?
| | RNA, Messenger | 3 | 2022 | 2832 | 0.110 |
Why?
| | Obesity | 2 | 2026 | 3082 | 0.110 |
Why?
| | Dose-Response Relationship, Drug | 1 | 2018 | 2032 | 0.100 |
Why?
| | Patient Discharge | 1 | 2020 | 983 | 0.100 |
Why?
| | Educational Measurement | 2 | 1993 | 326 | 0.100 |
Why?
| | Disease Progression | 1 | 2021 | 2852 | 0.100 |
Why?
| | Pancreatic Neoplasms | 1 | 2021 | 927 | 0.090 |
Why?
| | School Admission Criteria | 1 | 1993 | 34 | 0.090 |
Why?
| | Statistics, Nonparametric | 1 | 2013 | 427 | 0.090 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2010 | 194 | 0.090 |
Why?
| | Cricetulus | 1 | 2012 | 118 | 0.090 |
Why?
| | CHO Cells | 1 | 2012 | 171 | 0.090 |
Why?
| | Mutant Proteins | 1 | 2012 | 106 | 0.090 |
Why?
| | Reactive Oxygen Species | 2 | 2019 | 621 | 0.090 |
Why?
| | Cricetinae | 1 | 2012 | 304 | 0.090 |
Why?
| | End Stage Liver Disease | 1 | 2013 | 94 | 0.090 |
Why?
| | Caveolin 3 | 1 | 2011 | 2 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2016 | 3415 | 0.080 |
Why?
| | Valerates | 1 | 2010 | 3 | 0.080 |
Why?
| | Nitriles | 1 | 2012 | 205 | 0.080 |
Why?
| | Education, Medical, Undergraduate | 1 | 1993 | 207 | 0.080 |
Why?
| | Liver Cirrhosis | 1 | 2013 | 288 | 0.080 |
Why?
| | Mice, Nude | 1 | 2012 | 688 | 0.080 |
Why?
| | Weight Loss | 3 | 2011 | 837 | 0.080 |
Why?
| | Muscular Diseases | 1 | 2011 | 108 | 0.080 |
Why?
| | Proteasome Inhibitors | 1 | 2010 | 40 | 0.080 |
Why?
| | Mice, Inbred BALB C | 2 | 2010 | 1253 | 0.080 |
Why?
| | General Surgery | 1 | 1993 | 207 | 0.080 |
Why?
| | RNA, Small Interfering | 1 | 2012 | 635 | 0.080 |
Why?
| | Neoplasms, Experimental | 2 | 2010 | 173 | 0.080 |
Why?
| | Oxidative Stress | 2 | 2022 | 1339 | 0.080 |
Why?
| | Nutritional Status | 2 | 2013 | 354 | 0.080 |
Why?
| | Neuraminidase | 1 | 2009 | 25 | 0.070 |
Why?
| | Muscular Dystrophy, Duchenne | 1 | 2010 | 91 | 0.070 |
Why?
| | Neoplasm Transplantation | 1 | 2009 | 252 | 0.070 |
Why?
| | Biomarkers | 2 | 2018 | 4275 | 0.070 |
Why?
| | Rats | 6 | 2020 | 5614 | 0.070 |
Why?
| | Enzyme Inhibitors | 2 | 2009 | 826 | 0.070 |
Why?
| | Cytosol | 1 | 2009 | 227 | 0.070 |
Why?
| | Hypertension, Pulmonary | 1 | 2020 | 1980 | 0.070 |
Why?
| | Pyrimidines | 1 | 2012 | 533 | 0.070 |
Why?
| | Adult | 4 | 2026 | 40506 | 0.070 |
Why?
| | Pyrazoles | 1 | 2012 | 510 | 0.070 |
Why?
| | Aging | 1 | 2019 | 1966 | 0.070 |
Why?
| | Rats, Wistar | 4 | 2010 | 451 | 0.070 |
Why?
| | Nutritional Support | 1 | 2008 | 39 | 0.070 |
Why?
| | Retrospective Studies | 5 | 2026 | 17101 | 0.070 |
Why?
| | Teaching | 3 | 2005 | 236 | 0.060 |
Why?
| | Carcinoma, Hepatocellular | 1 | 2010 | 372 | 0.060 |
Why?
| | Autophagy | 1 | 2009 | 286 | 0.060 |
Why?
| | Heart Failure | 1 | 2020 | 2323 | 0.060 |
Why?
| | Protein Processing, Post-Translational | 1 | 2009 | 477 | 0.060 |
Why?
| | Quality of Life | 1 | 2018 | 3192 | 0.060 |
Why?
| | Gene Expression Regulation | 3 | 2010 | 2609 | 0.060 |
Why?
| | Role Playing | 1 | 2005 | 3 | 0.060 |
Why?
| | Myocardium | 1 | 2011 | 939 | 0.060 |
Why?
| | Transforming Growth Factor beta | 1 | 2008 | 479 | 0.060 |
Why?
| | Transcriptome | 1 | 2011 | 1046 | 0.050 |
Why?
| | Cells, Cultured | 1 | 2012 | 4155 | 0.050 |
Why?
| | Education, Medical, Continuing | 1 | 2005 | 132 | 0.050 |
Why?
| | Farms | 1 | 2023 | 8 | 0.050 |
Why?
| | Risk Factors | 3 | 2026 | 10792 | 0.050 |
Why?
| | Geologic Sediments | 1 | 2023 | 46 | 0.050 |
Why?
| | Cytochrome P-450 CYP1A2 | 1 | 2023 | 4 | 0.050 |
Why?
| | Cytochrome P-450 CYP1A1 | 1 | 2023 | 9 | 0.050 |
Why?
| | Dysbiosis | 1 | 2025 | 187 | 0.050 |
Why?
| | Receptors, Aryl Hydrocarbon | 1 | 2023 | 60 | 0.050 |
Why?
| | Neoplasm Invasiveness | 1 | 2024 | 509 | 0.050 |
Why?
| | Culture Media, Conditioned | 1 | 2022 | 111 | 0.050 |
Why?
| | Child | 1 | 2022 | 22657 | 0.050 |
Why?
| | Mice, SCID | 1 | 2022 | 369 | 0.040 |
Why?
| | Cathepsin K | 1 | 2021 | 1 | 0.040 |
Why?
| | Tartrate-Resistant Acid Phosphatase | 1 | 2021 | 5 | 0.040 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2021 | 25 | 0.040 |
Why?
| | Vacuolar Proton-Translocating ATPases | 1 | 2021 | 15 | 0.040 |
Why?
| | Apoptosis | 2 | 2021 | 2430 | 0.040 |
Why?
| | 3T3 Cells | 1 | 2021 | 156 | 0.040 |
Why?
| | Lipolysis | 1 | 2021 | 46 | 0.040 |
Why?
| | Myeloid Cells | 1 | 2022 | 148 | 0.040 |
Why?
| | Environmental Monitoring | 1 | 2023 | 378 | 0.040 |
Why?
| | Receptors, Leptin | 1 | 2020 | 25 | 0.040 |
Why?
| | Proto-Oncogene Proteins c-akt | 1 | 2022 | 437 | 0.040 |
Why?
| | Physician-Patient Relations | 1 | 2005 | 588 | 0.040 |
Why?
| | Microglia | 1 | 2022 | 269 | 0.040 |
Why?
| | Adipocytes | 1 | 2021 | 223 | 0.040 |
Why?
| | Estrogens | 1 | 2022 | 380 | 0.040 |
Why?
| | TOR Serine-Threonine Kinases | 1 | 2022 | 451 | 0.040 |
Why?
| | Receptors, LDL | 1 | 2019 | 53 | 0.040 |
Why?
| | Prevalence | 1 | 2026 | 2836 | 0.040 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2013 | 983 | 0.040 |
Why?
| | Surgical Flaps | 1 | 2020 | 142 | 0.040 |
Why?
| | AMP-Activated Protein Kinases | 1 | 2020 | 191 | 0.040 |
Why?
| | Neoplasm Metastasis | 1 | 2021 | 695 | 0.040 |
Why?
| | Europe | 1 | 1999 | 412 | 0.040 |
Why?
| | Biopsy | 2 | 2013 | 1077 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 889 | 0.030 |
Why?
| | Ubiquitin | 2 | 2010 | 86 | 0.030 |
Why?
| | Protein Biosynthesis | 1 | 2021 | 458 | 0.030 |
Why?
| | Imidazoles | 1 | 2019 | 254 | 0.030 |
Why?
| | Lung Neoplasms | 1 | 2011 | 2642 | 0.030 |
Why?
| | Adipose Tissue | 1 | 2021 | 653 | 0.030 |
Why?
| | Neoplasm Staging | 1 | 2020 | 1465 | 0.030 |
Why?
| | Metabolic Syndrome | 1 | 2020 | 354 | 0.030 |
Why?
| | Inflammation Mediators | 1 | 2019 | 509 | 0.030 |
Why?
| | Heart | 1 | 2020 | 636 | 0.030 |
Why?
| | Antihypertensive Agents | 1 | 2020 | 511 | 0.030 |
Why?
| | Biomechanical Phenomena | 1 | 2019 | 842 | 0.030 |
Why?
| | Logistic Models | 1 | 2020 | 2119 | 0.030 |
Why?
| | Health Status | 1 | 2020 | 836 | 0.030 |
Why?
| | Homeostasis | 1 | 2019 | 640 | 0.030 |
Why?
| | Transcription, Genetic | 1 | 2021 | 1496 | 0.030 |
Why?
| | Mice, Knockout | 1 | 2021 | 3125 | 0.030 |
Why?
| | Glucose | 1 | 2019 | 1049 | 0.020 |
Why?
| | Rectus Abdominis | 1 | 2013 | 16 | 0.020 |
Why?
| | Metabolomics | 1 | 2019 | 727 | 0.020 |
Why?
| | Curriculum | 1 | 1999 | 1060 | 0.020 |
Why?
| | Case-Control Studies | 1 | 2020 | 3608 | 0.020 |
Why?
| | Body Mass Index | 1 | 2020 | 2438 | 0.020 |
Why?
| | DNA Primers | 1 | 2013 | 512 | 0.020 |
Why?
| | Insulin Resistance | 1 | 2020 | 1241 | 0.020 |
Why?
| | Cell Differentiation | 1 | 2019 | 2050 | 0.020 |
Why?
| | Electroporation | 1 | 2010 | 41 | 0.020 |
Why?
| | Sarcoglycans | 1 | 2010 | 5 | 0.020 |
Why?
| | Dystroglycans | 1 | 2010 | 6 | 0.020 |
Why?
| | Hypoglycemic Agents | 1 | 2020 | 1389 | 0.020 |
Why?
| | Evans Blue | 1 | 2010 | 8 | 0.020 |
Why?
| | Bortezomib | 1 | 2010 | 55 | 0.020 |
Why?
| | Boronic Acids | 1 | 2010 | 37 | 0.020 |
Why?
| | Random Allocation | 1 | 2010 | 363 | 0.020 |
Why?
| | Forkhead Transcription Factors | 1 | 2010 | 202 | 0.020 |
Why?
| | Alkalies | 1 | 2009 | 5 | 0.020 |
Why?
| | Cathepsin L | 1 | 2009 | 9 | 0.020 |
Why?
| | Plasmids | 1 | 2010 | 379 | 0.020 |
Why?
| | Cathepsin B | 1 | 2009 | 16 | 0.020 |
Why?
| | Cathepsins | 1 | 2009 | 24 | 0.020 |
Why?
| | Pyrazines | 1 | 2010 | 93 | 0.020 |
Why?
| | Cysteine Endopeptidases | 1 | 2009 | 73 | 0.020 |
Why?
| | Mutation | 2 | 2011 | 4099 | 0.020 |
Why?
| | Aged, 80 and over | 1 | 2021 | 8279 | 0.020 |
Why?
| | Students, Medical | 1 | 1993 | 375 | 0.020 |
Why?
| | Lysosomes | 1 | 2009 | 128 | 0.020 |
Why?
| | Atrophy | 1 | 2009 | 201 | 0.020 |
Why?
| | Glycoproteins | 1 | 2010 | 355 | 0.020 |
Why?
| | Time Factors | 1 | 2019 | 7183 | 0.020 |
Why?
| | Polymerase Chain Reaction | 1 | 2010 | 1054 | 0.020 |
Why?
| | Dexamethasone | 1 | 2009 | 372 | 0.020 |
Why?
| | Formoterol Fumarate | 1 | 2006 | 6 | 0.020 |
Why?
| | Body Weight | 1 | 2010 | 978 | 0.020 |
Why?
| | Pentoxifylline | 1 | 2006 | 23 | 0.020 |
Why?
| | Ethanolamines | 1 | 2006 | 14 | 0.020 |
Why?
| | Receptor, IGF Type 1 | 1 | 2006 | 64 | 0.010 |
Why?
| | Adrenergic beta-Agonists | 1 | 2006 | 93 | 0.010 |
Why?
| | Blotting, Western | 1 | 2008 | 1187 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2008 | 1311 | 0.010 |
Why?
| | Energy Intake | 1 | 2008 | 500 | 0.010 |
Why?
| | Learning | 1 | 2005 | 452 | 0.010 |
Why?
| | Emotions | 1 | 2005 | 578 | 0.010 |
Why?
| | Insulin | 1 | 2009 | 2507 | 0.010 |
Why?
|
|
Bonetto's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|